[
    {
        "id": 3003,
        "drug_name": "ULTOMIRIS (ravulizumab-cwvz)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Paroxysmal nocturnal hemoglobinuria (PNH)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-12-21",
        "link": "http:\/\/ir.alexion.com\/news-releases\/news-release-details\/alexion-receives-early-fda-approval-ultomiristm-ravulizumab-cwvz",
        "note": "FDA approval announced December 21, 2018.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3868,
        "drug_name": "INBRIJA (CVT-301)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "OFF episodes of Parkinson\u2019s disease (PD)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-12-24",
        "link": "http:\/\/ir.acorda.com\/investors\/investor-news\/investor-news-details\/2018\/Acorda-Therapeutics-Announces-FDA-Approval-of-INBRIJA-levodopa-inhalation-powder\/default.aspx",
        "note": "FDA Approval announced December 22, 2018.",
        "company_entity_id": 7,
        "company_ticker": "ACOR",
        "company_name": "Acorda Therapeutics Inc.",
        "company_price": "12.6600",
        "company_change": 0.66,
        "company_percent_change": 5.5,
        "company_optionable": 0,
        "company_number_of_shares": 1242098,
        "price_change_sparkline": [
            [
                16.02,
                1706677200
            ],
            [
                15.85,
                1706763600
            ],
            [
                15.92,
                1706850000
            ],
            [
                15.3,
                1707109200
            ],
            [
                15.31,
                1707195600
            ],
            [
                15.15,
                1707282000
            ],
            [
                15.15,
                1707368400
            ],
            [
                15.4999,
                1707454800
            ],
            [
                15.14,
                1707714000
            ],
            [
                15.2001,
                1707800400
            ],
            [
                15.6,
                1707886800
            ],
            [
                15.2,
                1707973200
            ],
            [
                14.8,
                1708059600
            ],
            [
                13.9,
                1708405200
            ],
            [
                14.125,
                1708491600
            ],
            [
                13.5,
                1708578000
            ],
            [
                13.0461,
                1708664400
            ],
            [
                14.49,
                1708923600
            ],
            [
                13.4,
                1709010000
            ],
            [
                13.6001,
                1709096400
            ],
            [
                13.6001,
                1709182800
            ],
            [
                14.2,
                1709269200
            ],
            [
                13.01,
                1709528400
            ],
            [
                13,
                1709614800
            ],
            [
                13.3,
                1709701200
            ],
            [
                13.66,
                1709787600
            ],
            [
                12.79,
                1709874000
            ],
            [
                12,
                1710129600
            ],
            [
                12.04,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3738,
        "drug_name": "ANDEXXA (Andexanet alfa)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Factor Xa inhibitor reversal agent",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-12-31",
        "link": "http:\/\/investors.portola.com\/phoenix.zhtml?c=198136&p=irol-newsArticle&ID=2381753",
        "note": "Prior Approval Supplement (PAS) FDA Approval announced December 31, 2018.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5102,
        "drug_name": "Sprycel (dasatinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-01-02",
        "link": "https:\/\/news.bms.com\/press-release\/corporatefinancial-news\/bristol-myers-squibbs-sprycel-dasatinib-tablets-now-approved-c",
        "note": "FDA Approval announced January 2, 2019.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3518,
        "drug_name": "CABOMETYX (Cabozantinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Advanced hepatocellular cancer (HCC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-01-14",
        "link": "http:\/\/ir.exelixis.com\/phoenix.zhtml?c=120923&p=irol-newsArticle&ID=2383313",
        "note": "FDA Approval announced January 14, 2019.",
        "company_entity_id": 137,
        "company_ticker": "EXEL",
        "company_name": "Exelixis Inc.",
        "company_price": "22.6900",
        "company_change": 0.23,
        "company_percent_change": 1.02,
        "company_optionable": 1,
        "company_number_of_shares": 303194259,
        "price_change_sparkline": [
            [
                21.76,
                1706677200
            ],
            [
                21.75,
                1706763600
            ],
            [
                21.49,
                1706850000
            ],
            [
                21.4,
                1707109200
            ],
            [
                21.83,
                1707195600
            ],
            [
                20.18,
                1707282000
            ],
            [
                20.17,
                1707368400
            ],
            [
                20.22,
                1707454800
            ],
            [
                20.39,
                1707714000
            ],
            [
                20.23,
                1707800400
            ],
            [
                20.39,
                1707886800
            ],
            [
                20.59,
                1707973200
            ],
            [
                20.48,
                1708059600
            ],
            [
                20.63,
                1708405200
            ],
            [
                20.72,
                1708491600
            ],
            [
                20.71,
                1708578000
            ],
            [
                21.53,
                1708664400
            ],
            [
                21.96,
                1708923600
            ],
            [
                21.71,
                1709010000
            ],
            [
                21.91,
                1709096400
            ],
            [
                21.9,
                1709182800
            ],
            [
                22.24,
                1709269200
            ],
            [
                22.55,
                1709528400
            ],
            [
                22.26,
                1709614800
            ],
            [
                22.38,
                1709701200
            ],
            [
                22.09,
                1709787600
            ],
            [
                22.21,
                1709874000
            ],
            [
                22.46,
                1710129600
            ],
            [
                22.69,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3518,
        "drug_name": "CABOMETYX (Cabozantinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Advanced hepatocellular cancer (HCC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-01-14",
        "link": "http:\/\/ir.exelixis.com\/phoenix.zhtml?c=120923&p=irol-newsArticle&ID=2383313",
        "note": "FDA Approval announced January 14, 2019.",
        "company_entity_id": 751,
        "company_ticker": "TAK",
        "company_name": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1\/2 of a share of)",
        "company_price": "14.3700",
        "company_change": -0.19999999999999996,
        "company_percent_change": -1.37,
        "company_optionable": 1,
        "company_number_of_shares": 3137776702,
        "price_change_sparkline": [
            [
                14.6,
                1706677200
            ],
            [
                14.38,
                1706763600
            ],
            [
                14.28,
                1706850000
            ],
            [
                13.92,
                1707109200
            ],
            [
                14.16,
                1707195600
            ],
            [
                14.18,
                1707282000
            ],
            [
                14,
                1707368400
            ],
            [
                14.24,
                1707454800
            ],
            [
                14.31,
                1707714000
            ],
            [
                14.34,
                1707800400
            ],
            [
                14.54,
                1707886800
            ],
            [
                14.42,
                1707973200
            ],
            [
                14.62,
                1708059600
            ],
            [
                14.82,
                1708405200
            ],
            [
                14.74,
                1708491600
            ],
            [
                14.64,
                1708578000
            ],
            [
                14.62,
                1708664400
            ],
            [
                14.81,
                1708923600
            ],
            [
                14.84,
                1709010000
            ],
            [
                14.65,
                1709096400
            ],
            [
                14.59,
                1709182800
            ],
            [
                14.56,
                1709269200
            ],
            [
                14.48,
                1709528400
            ],
            [
                14.4,
                1709614800
            ],
            [
                14.69,
                1709701200
            ],
            [
                14.86,
                1709787600
            ],
            [
                14.77,
                1709874000
            ],
            [
                14.57,
                1710129600
            ],
            [
                14.37,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4848,
        "drug_name": "IMBRUVICA (Ibrutinib) and GAZYVA (Obinutuzumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-01-28",
        "link": "https:\/\/bit.ly\/2Sb6LSM",
        "note": "FDA approval announced January 28, 2019.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4809,
        "drug_name": "DWP-450",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Glabellar lines",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-02-01",
        "link": "https:\/\/investors.evolus.com\/news-releases\/news-release-details\/evolus-receives-fda-approval-jeuveautm-prabotulinumtoxina-xvfs",
        "note": "FDA Approval announced February 1, 2019.",
        "company_entity_id": 548,
        "company_ticker": "EOLS",
        "company_name": "Evolus Inc.",
        "company_price": "14.0900",
        "company_change": 0.08,
        "company_percent_change": 0.57,
        "company_optionable": 1,
        "company_number_of_shares": 57943622,
        "price_change_sparkline": [
            [
                12.69,
                1706677200
            ],
            [
                13.04,
                1706763600
            ],
            [
                13.47,
                1706850000
            ],
            [
                12.77,
                1707109200
            ],
            [
                13.05,
                1707195600
            ],
            [
                13.15,
                1707282000
            ],
            [
                13.36,
                1707368400
            ],
            [
                13.7,
                1707454800
            ],
            [
                13.73,
                1707714000
            ],
            [
                13.42,
                1707800400
            ],
            [
                13.52,
                1707886800
            ],
            [
                13.77,
                1707973200
            ],
            [
                13.52,
                1708059600
            ],
            [
                13.31,
                1708405200
            ],
            [
                13.07,
                1708491600
            ],
            [
                13.16,
                1708578000
            ],
            [
                13.72,
                1708664400
            ],
            [
                14.13,
                1708923600
            ],
            [
                14.54,
                1709010000
            ],
            [
                14.42,
                1709096400
            ],
            [
                14.83,
                1709182800
            ],
            [
                14.91,
                1709269200
            ],
            [
                14.74,
                1709528400
            ],
            [
                14.57,
                1709614800
            ],
            [
                14.11,
                1709701200
            ],
            [
                14.79,
                1709787600
            ],
            [
                14.07,
                1709874000
            ],
            [
                14.01,
                1710129600
            ],
            [
                14.09,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5472,
        "drug_name": "CABLIVI (caplacizumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Acquired thrombotic thrombocytopenic purpura (aTTP) ",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-02-06",
        "link": "http:\/\/www.news.sanofi.us\/2019-02-06-FDA-approves-Cablivi-R-caplacizumab-yhdp-the-first-Nanobody-R-based-medicine-for-adults-with-acquired-thrombotic-thrombocytopenic-purpura-aTTP",
        "note": "FDA Approval announced February 6, 2019.",
        "company_entity_id": 389,
        "company_ticker": "SNY",
        "company_name": "Sanofi",
        "company_price": "48.4600",
        "company_change": 0.11,
        "company_percent_change": 0.23,
        "company_optionable": 1,
        "company_number_of_shares": 2529599938,
        "price_change_sparkline": [
            [
                49.9,
                1706677200
            ],
            [
                48.41,
                1706763600
            ],
            [
                47.23,
                1706850000
            ],
            [
                46.95,
                1707109200
            ],
            [
                47.06,
                1707195600
            ],
            [
                46.92,
                1707282000
            ],
            [
                46.56,
                1707368400
            ],
            [
                46.5,
                1707454800
            ],
            [
                46.34,
                1707714000
            ],
            [
                45.75,
                1707800400
            ],
            [
                45.8,
                1707886800
            ],
            [
                46.39,
                1707973200
            ],
            [
                46.18,
                1708059600
            ],
            [
                46.85,
                1708405200
            ],
            [
                47.92,
                1708491600
            ],
            [
                47.8,
                1708578000
            ],
            [
                48.77,
                1708664400
            ],
            [
                48.2,
                1708923600
            ],
            [
                48.21,
                1709010000
            ],
            [
                48,
                1709096400
            ],
            [
                47.85,
                1709182800
            ],
            [
                47.29,
                1709269200
            ],
            [
                47.15,
                1709528400
            ],
            [
                47.5,
                1709614800
            ],
            [
                47.68,
                1709701200
            ],
            [
                48.06,
                1709787600
            ],
            [
                48.25,
                1709874000
            ],
            [
                48.35,
                1710129600
            ],
            [
                48.46,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5495,
        "drug_name": "EGATEN (triclabendazole)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Fascioliasis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-02-13",
        "link": "https:\/\/www.novartis.com\/news\/media-releases\/novartis-receives-fda-approval-egaten-treatment-fascioliasis-neglected-tropical-disease",
        "note": "FDA Approval announced February 13, 2019.",
        "company_entity_id": 386,
        "company_ticker": "NVS",
        "company_name": "Novartis AG",
        "company_price": "99.7700",
        "company_change": -1.6,
        "company_percent_change": -1.58,
        "company_optionable": 1,
        "company_number_of_shares": 2044033986,
        "price_change_sparkline": [
            [
                99.701426650332,
                1706677200
            ],
            [
                101.493681927897,
                1706763600
            ],
            [
                99.9423211768864,
                1706850000
            ],
            [
                99.701426650332,
                1707109200
            ],
            [
                99.9615927390107,
                1707195600
            ],
            [
                99.6917908692698,
                1707282000
            ],
            [
                97.6682768462129,
                1707368400
            ],
            [
                97.3502960711611,
                1707454800
            ],
            [
                96.8685070180523,
                1707714000
            ],
            [
                95.4520472019125,
                1707800400
            ],
            [
                95.4424114208503,
                1707886800
            ],
            [
                96.0012867224565,
                1707973200
            ],
            [
                96.5408904619384,
                1708059600
            ],
            [
                98.9787430706688,
                1708405200
            ],
            [
                98.824570573674,
                1708491600
            ],
            [
                99.0558293191662,
                1708578000
            ],
            [
                100.115765236006,
                1708664400
            ],
            [
                99.4894394669641,
                1708923600
            ],
            [
                99.3930816563424,
                1709010000
            ],
            [
                98.49695401756,
                1709096400
            ],
            [
                97.2924813847881,
                1709182800
            ],
            [
                98.3427815205652,
                1709269200
            ],
            [
                98.2560594910056,
                1709528400
            ],
            [
                98.3813246448139,
                1709614800
            ],
            [
                98.9016568221714,
                1709701200
            ],
            [
                99.93,
                1709787600
            ],
            [
                100.71,
                1709874000
            ],
            [
                101.37,
                1710129600
            ],
            [
                99.77,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2209,
        "drug_name": "KEYTRUDA (pembrolizumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Melanoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-02-19",
        "link": "https:\/\/bit.ly\/2Ixomkq",
        "note": "FDA Approval announced February 19, 2019.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4535,
        "drug_name": "ESPEROCT (N8-GP)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Hemophilia A",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-02-19",
        "link": "https:\/\/www.novonordisk.com\/media\/news-details.2235689.html",
        "note": "FDA Approval announced February 19, 2019.",
        "company_entity_id": 385,
        "company_ticker": "NVO",
        "company_name": "Novo Nordisk A\/S",
        "company_price": "135.1100",
        "company_change": 3.87,
        "company_percent_change": 2.95,
        "company_optionable": 1,
        "company_number_of_shares": 4510000000,
        "price_change_sparkline": [
            [
                114.74,
                1706677200
            ],
            [
                115.79,
                1706763600
            ],
            [
                113.7,
                1706850000
            ],
            [
                118.26,
                1707109200
            ],
            [
                117.61,
                1707195600
            ],
            [
                118.66,
                1707282000
            ],
            [
                118.39,
                1707368400
            ],
            [
                121.2,
                1707454800
            ],
            [
                120.53,
                1707714000
            ],
            [
                119.99,
                1707800400
            ],
            [
                123.29,
                1707886800
            ],
            [
                121.75,
                1707973200
            ],
            [
                124.01,
                1708059600
            ],
            [
                121.45,
                1708405200
            ],
            [
                120.93,
                1708491600
            ],
            [
                124.52,
                1708578000
            ],
            [
                123.45,
                1708664400
            ],
            [
                123.49,
                1708923600
            ],
            [
                122.23,
                1709010000
            ],
            [
                121.54,
                1709096400
            ],
            [
                119.77,
                1709182800
            ],
            [
                124.23,
                1709269200
            ],
            [
                127.95,
                1709528400
            ],
            [
                124.65,
                1709614800
            ],
            [
                124.75,
                1709701200
            ],
            [
                135.92,
                1709787600
            ],
            [
                133.07,
                1709874000
            ],
            [
                131.24,
                1710129600
            ],
            [
                135.11,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2775,
        "drug_name": "Loteprednol Gel 0.38%",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Ocular Inflammation",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-02-25",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/bausch--lomb-announces-fda-approval-of-lotemax-sm-loteprednol-etabonate-ophthalmic-gel-0-38-for-the-treatment-of-postoperative-inflammation-and-pain-following-ocular-surgery-300800968.html",
        "note": "FDA approval announced February 25, 2019.",
        "company_entity_id": 574,
        "company_ticker": "BHC",
        "company_name": "Bausch Health Companies Inc.",
        "company_price": "9.1900",
        "company_change": 0.07,
        "company_percent_change": 0.77,
        "company_optionable": 1,
        "company_number_of_shares": 365411953,
        "price_change_sparkline": [
            [
                7.85,
                1706677200
            ],
            [
                7.98,
                1706763600
            ],
            [
                7.92,
                1706850000
            ],
            [
                7.77,
                1707109200
            ],
            [
                8.13,
                1707195600
            ],
            [
                8.12,
                1707282000
            ],
            [
                8.13,
                1707368400
            ],
            [
                8.21,
                1707454800
            ],
            [
                8.38,
                1707714000
            ],
            [
                8.41,
                1707800400
            ],
            [
                8.43,
                1707886800
            ],
            [
                8.49,
                1707973200
            ],
            [
                8.51,
                1708059600
            ],
            [
                8.6,
                1708405200
            ],
            [
                8.67,
                1708491600
            ],
            [
                9.3,
                1708578000
            ],
            [
                9.18,
                1708664400
            ],
            [
                8.99,
                1708923600
            ],
            [
                9.18,
                1709010000
            ],
            [
                9.2,
                1709096400
            ],
            [
                9.39,
                1709182800
            ],
            [
                9.89,
                1709269200
            ],
            [
                9.58,
                1709528400
            ],
            [
                9.56,
                1709614800
            ],
            [
                9.23,
                1709701200
            ],
            [
                9.28,
                1709787600
            ],
            [
                9.23,
                1709874000
            ],
            [
                9.12,
                1710129600
            ],
            [
                9.19,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5237,
        "drug_name": "APC-8000 (sublingual tadalafil)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Erectile dysfunction",
        "label": "NDA Filing",
        "value": "ndaFiling",
        "simplified_stage": "phase4",
        "stageid": 10,
        "stage_name": "NDA Filing",
        "date": "2019-02-26",
        "link": "http:\/\/ir.adamispharmaceuticals.com\/news-releases\/news-release-details\/adamis-provides-regulatory-update-sublingual-tadalafil",
        "note": "Refusal to file letter received February 26, 2019.",
        "company_entity_id": 15,
        "company_ticker": "ADMP",
        "company_name": "DMK Pharmaceuticals Corp Com Par $0.001",
        "company_price": "0.7751",
        "company_change": 0.01,
        "company_percent_change": 0.85,
        "company_optionable": 0,
        "company_number_of_shares": 9359133,
        "statuses": []
    },
    {
        "id": 4034,
        "drug_name": "CINVANTI (HTX-019)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Prevention of chemotherapy-induced nausea and vomiting (CINV)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-02-26",
        "link": "https:\/\/herontherapeutics.gcs-web.com\/news-releases\/news-release-details\/heron-announces-fda-approval-supplemental-new-drug-application",
        "note": "FDA additional approval allowing  IV injection in addition to current IV infusion.",
        "company_entity_id": 157,
        "company_ticker": "HRTX",
        "company_name": "Heron Therapeutics Inc.",
        "company_price": "2.3600",
        "company_change": -0.050000000000000044,
        "company_percent_change": -2.07,
        "company_optionable": 1,
        "company_number_of_shares": 150072640,
        "price_change_sparkline": [
            [
                2.41,
                1706677200
            ],
            [
                2.4,
                1706763600
            ],
            [
                2.39,
                1706850000
            ],
            [
                2.23,
                1707109200
            ],
            [
                2.32,
                1707195600
            ],
            [
                2.26,
                1707282000
            ],
            [
                2.35,
                1707368400
            ],
            [
                2.43,
                1707454800
            ],
            [
                2.63,
                1707714000
            ],
            [
                2.51,
                1707800400
            ],
            [
                2.72,
                1707886800
            ],
            [
                2.88,
                1707973200
            ],
            [
                2.87,
                1708059600
            ],
            [
                2.87,
                1708405200
            ],
            [
                2.75,
                1708491600
            ],
            [
                2.62,
                1708578000
            ],
            [
                2.6,
                1708664400
            ],
            [
                2.6,
                1708923600
            ],
            [
                2.74,
                1709010000
            ],
            [
                2.7,
                1709096400
            ],
            [
                2.66,
                1709182800
            ],
            [
                2.61,
                1709269200
            ],
            [
                2.555,
                1709528400
            ],
            [
                2.56,
                1709614800
            ],
            [
                2.48,
                1709701200
            ],
            [
                2.59,
                1709787600
            ],
            [
                2.6,
                1709874000
            ],
            [
                2.41,
                1710129600
            ],
            [
                2.36,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5544,
        "drug_name": "TREMFYA (Guselkumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Plaque psoriasis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-02-27",
        "link": "https:\/\/johnsonandjohnson.gcs-web.com\/static-files\/15a98bf7-f200-4be6-bb4f-ce7603dcd15a",
        "note": "Approval announced February 27, 2019.",
        "company_entity_id": 538,
        "company_ticker": "MOR",
        "company_name": "MorphoSys AG",
        "company_price": "18.1700",
        "company_change": 0.28,
        "company_percent_change": 1.5699999999999998,
        "company_optionable": 1,
        "company_number_of_shares": 136927772,
        "price_change_sparkline": [
            [
                10.51,
                1706677200
            ],
            [
                11.505,
                1706763600
            ],
            [
                11.07,
                1706850000
            ],
            [
                17.27,
                1707109200
            ],
            [
                16.27,
                1707195600
            ],
            [
                17,
                1707282000
            ],
            [
                17.15,
                1707368400
            ],
            [
                17.15,
                1707454800
            ],
            [
                17.33,
                1707714000
            ],
            [
                17.18,
                1707800400
            ],
            [
                17.43,
                1707886800
            ],
            [
                17.49,
                1707973200
            ],
            [
                17.48,
                1708059600
            ],
            [
                17.59,
                1708405200
            ],
            [
                17.65,
                1708491600
            ],
            [
                17.71,
                1708578000
            ],
            [
                17.62,
                1708664400
            ],
            [
                17.69,
                1708923600
            ],
            [
                17.67,
                1709010000
            ],
            [
                17.58,
                1709096400
            ],
            [
                17.6,
                1709182800
            ],
            [
                17.7,
                1709269200
            ],
            [
                17.74,
                1709528400
            ],
            [
                17.69,
                1709614800
            ],
            [
                17.8,
                1709701200
            ],
            [
                17.85,
                1709787600
            ],
            [
                17.91,
                1709874000
            ],
            [
                17.89,
                1710129600
            ],
            [
                18.17,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5544,
        "drug_name": "TREMFYA (Guselkumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Plaque psoriasis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-02-27",
        "link": "https:\/\/johnsonandjohnson.gcs-web.com\/static-files\/15a98bf7-f200-4be6-bb4f-ce7603dcd15a",
        "note": "Approval announced February 27, 2019.",
        "company_entity_id": 380,
        "company_ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "company_price": "162.7400",
        "company_change": 1.51,
        "company_percent_change": 0.94,
        "company_optionable": 1,
        "company_number_of_shares": 2408767228,
        "price_change_sparkline": [
            [
                157.701248890579,
                1706677200
            ],
            [
                157.165322682896,
                1706763600
            ],
            [
                155.428524787625,
                1706850000
            ],
            [
                154.6246354761,
                1707109200
            ],
            [
                156.867585900849,
                1707195600
            ],
            [
                156.788189425637,
                1707282000
            ],
            [
                155.220109040193,
                1707368400
            ],
            [
                155.577393178648,
                1707454800
            ],
            [
                156.659170153417,
                1707714000
            ],
            [
                155.289580956004,
                1707800400
            ],
            [
                154.565088119691,
                1707886800
            ],
            [
                156.728642069228,
                1707973200
            ],
            [
                156.55,
                1708059600
            ],
            [
                157.86,
                1708405200
            ],
            [
                158.68,
                1708491600
            ],
            [
                160.45,
                1708578000
            ],
            [
                161.84,
                1708664400
            ],
            [
                160.79,
                1708923600
            ],
            [
                160.98,
                1709010000
            ],
            [
                161.55,
                1709096400
            ],
            [
                161.38,
                1709182800
            ],
            [
                162.12,
                1709269200
            ],
            [
                159.84,
                1709528400
            ],
            [
                159.97,
                1709614800
            ],
            [
                159.34,
                1709701200
            ],
            [
                158.87,
                1709787600
            ],
            [
                159.52,
                1709874000
            ],
            [
                161.23,
                1710129600
            ],
            [
                162.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5407,
        "drug_name": "HERCEPTIN (Trastuzumab) using ENHANZE",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Breast cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-02-28",
        "link": "https:\/\/www.halozyme.com\/investors\/news-releases\/news-release-details\/2019\/Halozyme-Announces-FDA-Approval-Of-Herceptin-Hylecta\/default.aspx",
        "note": "FDA approval announced February 28, 2019.",
        "company_entity_id": 156,
        "company_ticker": "HALO",
        "company_name": "Halozyme Therapeutics Inc.",
        "company_price": "41.9500",
        "company_change": 0.75,
        "company_percent_change": 1.8199999999999998,
        "company_optionable": 1,
        "company_number_of_shares": 126824800,
        "price_change_sparkline": [
            [
                33.85,
                1706677200
            ],
            [
                34.26,
                1706763600
            ],
            [
                33.68,
                1706850000
            ],
            [
                33.68,
                1707109200
            ],
            [
                35.02,
                1707195600
            ],
            [
                35.31,
                1707282000
            ],
            [
                35.24,
                1707368400
            ],
            [
                35.49,
                1707454800
            ],
            [
                35.69,
                1707714000
            ],
            [
                34.64,
                1707800400
            ],
            [
                35.06,
                1707886800
            ],
            [
                35.91,
                1707973200
            ],
            [
                36.1,
                1708059600
            ],
            [
                36,
                1708405200
            ],
            [
                38.36,
                1708491600
            ],
            [
                39.72,
                1708578000
            ],
            [
                40.56,
                1708664400
            ],
            [
                39.67,
                1708923600
            ],
            [
                39.84,
                1709010000
            ],
            [
                39.69,
                1709096400
            ],
            [
                39.81,
                1709182800
            ],
            [
                41.11,
                1709269200
            ],
            [
                40.93,
                1709528400
            ],
            [
                41.41,
                1709614800
            ],
            [
                41.69,
                1709701200
            ],
            [
                41.71,
                1709787600
            ],
            [
                41.73,
                1709874000
            ],
            [
                41.2,
                1710129600
            ],
            [
                41.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2878,
        "drug_name": "SPRAVATO (esketamine)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Treatment resistant depression ",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-03-05",
        "link": "https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm632761.htm",
        "note": "FDA approval announced March 5, 2019.",
        "company_entity_id": 380,
        "company_ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "company_price": "162.7400",
        "company_change": 1.51,
        "company_percent_change": 0.94,
        "company_optionable": 1,
        "company_number_of_shares": 2408767228,
        "price_change_sparkline": [
            [
                157.701248890579,
                1706677200
            ],
            [
                157.165322682896,
                1706763600
            ],
            [
                155.428524787625,
                1706850000
            ],
            [
                154.6246354761,
                1707109200
            ],
            [
                156.867585900849,
                1707195600
            ],
            [
                156.788189425637,
                1707282000
            ],
            [
                155.220109040193,
                1707368400
            ],
            [
                155.577393178648,
                1707454800
            ],
            [
                156.659170153417,
                1707714000
            ],
            [
                155.289580956004,
                1707800400
            ],
            [
                154.565088119691,
                1707886800
            ],
            [
                156.728642069228,
                1707973200
            ],
            [
                156.55,
                1708059600
            ],
            [
                157.86,
                1708405200
            ],
            [
                158.68,
                1708491600
            ],
            [
                160.45,
                1708578000
            ],
            [
                161.84,
                1708664400
            ],
            [
                160.79,
                1708923600
            ],
            [
                160.98,
                1709010000
            ],
            [
                161.55,
                1709096400
            ],
            [
                161.38,
                1709182800
            ],
            [
                162.12,
                1709269200
            ],
            [
                159.84,
                1709528400
            ],
            [
                159.97,
                1709614800
            ],
            [
                159.34,
                1709701200
            ],
            [
                158.87,
                1709787600
            ],
            [
                159.52,
                1709874000
            ],
            [
                161.23,
                1710129600
            ],
            [
                162.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5385,
        "drug_name": "TECENTRIQ (atezolizumab) plus Abraxane",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Triple-negative breast cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-03-08",
        "link": "https:\/\/www.cancerresearch.org\/blog\/march-2019\/fda-approval-atezolizumab-triple-neg-breast-cancer",
        "note": "FDA Approval announced March 8, 2019.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5385,
        "drug_name": "TECENTRIQ (atezolizumab) plus Abraxane",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Triple-negative breast cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-03-08",
        "link": "https:\/\/www.cancerresearch.org\/blog\/march-2019\/fda-approval-atezolizumab-triple-neg-breast-cancer",
        "note": "FDA Approval announced March 8, 2019.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2738,
        "drug_name": "DUPIXENT (dupilumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Atopic dermatitis 12-17 year-olds",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-03-11",
        "link": "https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/fda-approves-dupixentr-dupilumab-moderate-severe-atopic",
        "note": "FDA approval announced March 11, 2019.",
        "company_entity_id": 388,
        "company_ticker": "REGN",
        "company_name": "Regeneron Pharmaceuticals Inc.",
        "company_price": "970.5700",
        "company_change": 6.13,
        "company_percent_change": 0.64,
        "company_optionable": 1,
        "company_number_of_shares": 109761896,
        "price_change_sparkline": [
            [
                942.78,
                1706677200
            ],
            [
                957.78,
                1706763600
            ],
            [
                945.18,
                1706850000
            ],
            [
                936.33,
                1707109200
            ],
            [
                937.81,
                1707195600
            ],
            [
                938.49,
                1707282000
            ],
            [
                946.43,
                1707368400
            ],
            [
                953.42,
                1707454800
            ],
            [
                947.06,
                1707714000
            ],
            [
                940.48,
                1707800400
            ],
            [
                947.82,
                1707886800
            ],
            [
                954.73,
                1707973200
            ],
            [
                948.05,
                1708059600
            ],
            [
                946.87,
                1708405200
            ],
            [
                952.84,
                1708491600
            ],
            [
                964.89,
                1708578000
            ],
            [
                981.2,
                1708664400
            ],
            [
                989.28,
                1708923600
            ],
            [
                993.35,
                1709010000
            ],
            [
                987.61,
                1709096400
            ],
            [
                966.09,
                1709182800
            ],
            [
                982.82,
                1709269200
            ],
            [
                971.19,
                1709528400
            ],
            [
                965.21,
                1709614800
            ],
            [
                972.1,
                1709701200
            ],
            [
                973.31,
                1709787600
            ],
            [
                968.83,
                1709874000
            ],
            [
                964.44,
                1710129600
            ],
            [
                970.57,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2738,
        "drug_name": "DUPIXENT (dupilumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Atopic dermatitis 12-17 year-olds",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-03-11",
        "link": "https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/fda-approves-dupixentr-dupilumab-moderate-severe-atopic",
        "note": "FDA approval announced March 11, 2019.",
        "company_entity_id": 389,
        "company_ticker": "SNY",
        "company_name": "Sanofi",
        "company_price": "48.4600",
        "company_change": 0.11,
        "company_percent_change": 0.23,
        "company_optionable": 1,
        "company_number_of_shares": 2529599938,
        "price_change_sparkline": [
            [
                49.9,
                1706677200
            ],
            [
                48.41,
                1706763600
            ],
            [
                47.23,
                1706850000
            ],
            [
                46.95,
                1707109200
            ],
            [
                47.06,
                1707195600
            ],
            [
                46.92,
                1707282000
            ],
            [
                46.56,
                1707368400
            ],
            [
                46.5,
                1707454800
            ],
            [
                46.34,
                1707714000
            ],
            [
                45.75,
                1707800400
            ],
            [
                45.8,
                1707886800
            ],
            [
                46.39,
                1707973200
            ],
            [
                46.18,
                1708059600
            ],
            [
                46.85,
                1708405200
            ],
            [
                47.92,
                1708491600
            ],
            [
                47.8,
                1708578000
            ],
            [
                48.77,
                1708664400
            ],
            [
                48.2,
                1708923600
            ],
            [
                48.21,
                1709010000
            ],
            [
                48,
                1709096400
            ],
            [
                47.85,
                1709182800
            ],
            [
                47.29,
                1709269200
            ],
            [
                47.15,
                1709528400
            ],
            [
                47.5,
                1709614800
            ],
            [
                47.68,
                1709701200
            ],
            [
                48.06,
                1709787600
            ],
            [
                48.25,
                1709874000
            ],
            [
                48.35,
                1710129600
            ],
            [
                48.46,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3888,
        "drug_name": "ROCLATAN (netarsudil\/latanoprost ophthalmic solution)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Glaucoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-03-13",
        "link": "http:\/\/investors.aeriepharma.com\/news-releases\/news-release-details\/aerie-pharmaceuticals-announces-us-fda-approval-rocklatantm",
        "note": "FDA Approval announced March 12, 2019.",
        "company_entity_id": 1437,
        "company_ticker": "ALC",
        "company_name": "Alcon Inc.",
        "company_price": "88.1300",
        "company_change": -0.020000000000000018,
        "company_percent_change": -0.020000000000000018,
        "company_optionable": 1,
        "company_number_of_shares": 499700000,
        "price_change_sparkline": [
            [
                75.11,
                1706677200
            ],
            [
                76.39,
                1706763600
            ],
            [
                74.98,
                1706850000
            ],
            [
                75.4,
                1707109200
            ],
            [
                76.93,
                1707195600
            ],
            [
                76.86,
                1707282000
            ],
            [
                77.17,
                1707368400
            ],
            [
                77.2,
                1707454800
            ],
            [
                77.34,
                1707714000
            ],
            [
                74.84,
                1707800400
            ],
            [
                76.44,
                1707886800
            ],
            [
                77.88,
                1707973200
            ],
            [
                77.54,
                1708059600
            ],
            [
                78.31,
                1708405200
            ],
            [
                79.78,
                1708491600
            ],
            [
                80.4,
                1708578000
            ],
            [
                80.06,
                1708664400
            ],
            [
                80.53,
                1708923600
            ],
            [
                81.18,
                1709010000
            ],
            [
                85.69,
                1709096400
            ],
            [
                84.55,
                1709182800
            ],
            [
                86.74,
                1709269200
            ],
            [
                85.91,
                1709528400
            ],
            [
                85,
                1709614800
            ],
            [
                85.75,
                1709701200
            ],
            [
                86.92,
                1709787600
            ],
            [
                87.28,
                1709874000
            ],
            [
                88.15,
                1710129600
            ],
            [
                88.13,
                1710216000
            ]
        ],
        "statuses": []
    }
]